Very Long-Term Prognostic Role of Admission BNP in Non-ST Segment Elevation Acute Coronary Syndrome

Abstract

Background:

BNP has been extensively evaluated to determine short- and intermediate-term prognosis in patients with acute coronary syndrome, but its role in long-term mortality is not known.

Objective:

To determine the very long-term prognostic role of B-type natriuretic peptide (BNP) for all-cause mortality in patients with non-ST segment elevation acute coronary syndrome (NSTEACS).

Methods:

A cohort of 224 consecutive patients with NSTEACS, prospectively seen in the Emergency Department, had BNP measured on arrival to establish prognosis, and underwent a median 9.34-year follow-up for all-cause mortality.

Results:

Unstable angina was diagnosed in 52.2%, and non-ST segment elevation myocardial infarction, in 47.8%. Median admission BNP was 81.9 pg/mL (IQ range = 22.2; 225) and mortality rate was correlated with increasing BNP quartiles: 14.3; 16.1; 48.2; and 73.2% (p < 0.0001). ROC curve disclosed 100 pg/mL as the best BNP cut-off value for mortality prediction (area under the curve = 0.789, 95% CI= 0.723-0.854), being a strong predictor of late mortality: BNP < 100 = 17.3% vs. BNP ≥ 100 = 65.0%, RR = 3.76 (95% CI = 2.49-5.63, p < 0.001). On logistic regression analysis, age >72 years (OR = 3.79, 95% CI = 1.62-8.86, p = 0.002), BNP ≥ 100 pg/mL (OR = 6.24, 95% CI = 2.95-13.23, p < 0.001) and estimated glomerular filtration rate (OR = 0.98, 95% CI = 0.97-0.99, p = 0.049) were independent late-mortality predictors.

Conclusions:

BNP measured at hospital admission in patients with NSTEACS is a strong, independent predictor of very long-term all-cause mortality. This study allows raising the hypothesis that BNP should be measured in all patients with NSTEACS at the index event for long-term risk stratification.

Keywords:
Natriuretic Peptide, B-Type / mortality; Prognosis; Acute Coronary Syndrome; Myocardial Ischemia

Resumo

Fundamento:

O BNP foi exaustivamente avaliado para a determinação do prognóstico em curto e médio prazo em pacientes com síndrome coronariana aguda, mas o seu papel para a mortalidade a longo prazo é incerta.

Objetivo:

Determinar o papel prognóstico a muito longo prazo do peptídeo natriurético do tipo B (BNP) para a mortalidade por todas as causas em pacientes com síndrome coronariana aguda sem supradesnivelamento do segmento ST (SCASSST).

Métodos:

Coorte de 224 pacientes consecutivos com SCASSST, prospectivamente atendidos no setor de emergência, em que se mediu o BNP na chegada para estabelecer o prognóstico ao longo do seguimento mediano de 9,34 anos para a mortalidade por todas as causas.

Resultados:

Diagnosticou-se angina instável em 52,2% e infarto do miocárdio sem supradesnivelamento do segmento ST em 47,8%. A mediana do BNP da admissão foi de 81,9 pg/mL (intervalo IQ = 22,2; 225) e a taxa de mortalidade correlacionou-se com quartis crescentes de BNP: 14,3; 16,1; 48,2; e 73,2% (p < 0,0001). A curva ROC revelou 100 pg/mL como o melhor ponto de corte de BNP para a predição de mortalidade (área sob a curva = 0,789, 95% CI = 0,723-0,854) sendo um forte preditor de mortalidade tardia: BNP < 100 = 17,3% vs. BNP ≥ 100 = 65,0%, RR = 3,76 (IC 95% = 2,49-5,63, p < 0,001). Na análise de regressão logística, idade>72 anos (OR = 3,79, IC 95% = 1,62-8,86, p = 0,002), BNP ≥ 100 pg/mL (OR = 6,24, IC 95% = 2,95-13,23, p < 0,001) e taxa de filtração glomerular estimada (OR = 0,98, IC 95% = 0,97-0,99, p = 0,049) foram preditores independentes de mortalidade tardia.

Conclusões:

O BNP medido na admissão hospitalar em pacientes com SCASSST é um forte preditor independente de mortalidade por todas as causas de muito longo prazo. Este estudo permite que se levante a hipótese de que o BNP deva ser medido em todos os pacientes com SCASSST no evento-índice para a estratificação de risco a longo prazo.

Palavras-chave:
Peptídeo Natriurético Tipo B / mortalidade; Prognóstico; Síndrome Coronariana Aguda; Isquemia Miocárdica

Introduction

In spite of the large knowledge gathered in the last few decades in identifying clinical and laboratory variables to determine short- and intermediate-term prognosis in patients with acute coronary syndrome (ACS),^1-5 their long-term prediction capability remains mostly unknown. B-type natriuretic peptides (BNP) are one of these markers and have been extensively evaluated for this purpose with very good performance,^6-10 but no study has dealt with their value in correctly identifying those individuals at high risk of death in the very long-term.

We had the opportunity to prospectively, systematically collect clinical and laboratory data in a cohort of patients examined in the Chest Pain Unit of an Emergency Department, to whom a comprehensive diagnostic and risk-stratification protocol was used.¹¹ Several clinical and laboratory markers were evaluated upon admission to establish the diagnosis of ACS. Patients were then treated accordingly and followed up to determine their long-term natural history. The aim of this study was to determine the prognostic role of the admission BNP level in the 10-year all-cause mortality of those individuals who had a final diagnosis of non-ST segment elevation ACS (NSTEACS).

Methods

Study population and data collection

We prospectively studied 723 consecutive patients seen in the Emergency Department of the Pró-Cardíaco Hospital, a private, tertiary, cardiology-oriented institution in Rio de Janeiro, Brazil, between January 1^st, 2002, and December 31^st, 2003. They complained of chest pain or discomfort in the preceding 12 hours due to possible acute cardiac ischemia, and their admission electrocardiogram (ECG) showed no ST-segment elevation. These patients were routinely managed in the Chest Pain Unit with a systematic diagnostic protocol recommending the following: 1) cardiac markers: admission and serial (every 3 hours) creatine kinase-MB mass (CKMB) and/or troponin-I levels; 2) admission and serial ECG; 3) echocardiogram (in many patients); 4) if neither myocardial necrosis nor rest ischemia were detected, a stress test (either treadmill ECG or single-photon emission computed tomographic myocardial scintigraphy). Coronary angiography and revascularization procedure were performed at the discretion of the attending physician. TIMI risk score was calculated in all patients fulfilling the diagnosis of ACS. Based on the above work-up, 237 patients received a final diagnosis of NSTEACS, constituting the initial study population. Of these, 13 individuals were lost sometime during the 10-year follow-up. The remaining 224 patients represent the final study sample.

Patients with suspected (intermediate to high pretest probability) or straightforward admitting diagnosis of life-threatening disorders other than ACS, such as aortic dissection and pulmonary embolism, were also immediately submitted to appropriate imaging tests and, if confirmed, diverted from the above mentioned diagnostic pathway. These patients were excluded from this study.

For this prospective study, plasma BNP was incorporated into the diagnostic protocol and obtained on admission with the purpose of correlating BNP with the final discharge diagnosis and follow-up prognosis. BNP results were available to treating physicians. This study complies with the Declaration of Helsinki and its protocol was approved by the hospital ethics committee. All patients provided written informed consent.

Biochemical analysis

Plasma BNP was immediately analyzed on the same EDTA-anticoagulated blood sample collected on admission for troponin-I, using the quantitative immunofluorescence assay (Biosite, California, USA). The analytic sensitivity of the assay is less than 5 pg/mL and the upper normal limit is considered to be 100 pg/mL. Plasma troponin-I was measured by immunofluorescence assay (Dade-Behring, Marburg, Germany). The analytic sensitivity of the assay is 0.1 ng/mL and any value above this was considered diagnostic of non-ST-segment elevation myocardial infarction (NSTEMI) in this study.^12,13 The coefficient of variation of the 99th percentile of the diagnostic value of the assay (0.1 ng/mL) is 10%.

Clinical data and diagnosis on hospital discharge

All demographic and clinical data were prospectively obtained on hospital admission and during Emergency Department and hospital stay until final diagnosis was reached. NSTEMI was diagnosed when a troponin-I level above 0.1 ng/mL in any sample was found during the first 9 post-admission hours with a rise and/or fall pattern afterwards, with or without ST-T changes on ECG, in the absence of any other demonstrable cause for the chest pain. Unstable angina was diagnosed when, in the absence of the above troponin-I pattern, suggestive chest pain was associated with either transient ST-segment depression (≥ 0.1 mV) or T-wave inversion on ECG, pre-discharge ischemic stress test or significant coronary artery disease on angiography. Absence of ACS was diagnosed when complete diagnostic protocol was performed in the Chest Pain Unit and demonstrated neither myocardial necrosis nor ischemia. Patients who showed increased troponin-I levels after undergoing percutaneous coronary angioplasty were not considered to have myocardial infarction. TIMI risk score was calculated upon hospital admission and classified as low (0-2 points), intermediate (3-4 points) and high risk (5-7 points).

Clinical endpoints

After hospital discharge, the patients' clinical status was prospectively determined by programmed telephone calls at 1 month, 1 year and 10 years. When any clinical event was reported by the patient or close relative, the hospital chart was reviewed or the private physician was contacted to establish the type of event or death. The primary endpoint of the study was all-cause death. At 10 years, 13 patients (5.5%) were lost to follow-up.

Statistical analysis

All data analyses were performed using Stata Program 12.1 (StataCorp 2011). Plasma concentrations of BNP are described as median and interquartile (IQ) range. All sample measurements had their 95% confidence interval (CI) calculated according to the maximum likelihood estimation method. For all statistical analyses, a p-value ≤ 0.05 was considered significant.

Differences in proportions were assessed by using the chi-square method. The Mann-Whitney test was used to compare BNP levels between two independent groups (with or without 10-year all-cause death).

The bivariate analysis between BNP level quartiles and clinical variables and mortality was calculated by using the chi-square method for trend or the Fisher exact test.

Receiver operating characteristic (ROC) curves were generated and the area under the curve (and its 95% CI) was calculated to determine the best discriminating BNP level obtained on admission for predicting all-cause mortality.

Sensitivity, specificity, positive and negative predictive values, and 95% CI were calculated in the usual manner. Hazard ratio values were corrected when necessary to avoid calculation bias.

Cumulative 10-year survival was determined by the Kaplan-Meier method. Difference in survival according to BNP level was evaluated with a log-rank test and Cox proportional risk model.

Main effects logistic regression analyses were used to establish the predictive relationship between continuous or dichotomized BNP levels and mortality adjusted for the effects of clinical and laboratory variables. Initially, all significant variables identified on univariate analysis were included in the models. Variables were selected by use of the forward stepwise method guided by likelihood ratio, and respective c-statistics was calculated. Modeling was performed, refusing entry to variables with p > 0.10.

The increased discriminative value after addition of BNP to the established prognostic factors for 10-year mortality was estimated by using the integrated discrimination improvement (IDI) technique.¹⁴ IDI was calculated by analyzing the differences in patients' individual estimated probability of mortality after addition of BNP to a model containing the aforementioned established prognostic factors and represents the average improvement in predicted probability. Results were assessed by absolute and relative differences in discrimination values between models.

Results

Patients characteristics

From this cohort of 224 consecutive NSTEACS patients, 107 (47.8%) had a final diagnosis of myocardial infarction and 117 (52.2%), of unstable angina. Demographic and clinical characteristics are depicted in Table 1. TIMI risk score could be calculated in 202 of the 224 NSTEACS patients, most of whom were classified either as low or intermediate risk.

Table 1
Baseline clinical and laboratory data of 224 patients with non-ST elevation acute coronary syndrome

Clinical characteristics	n = 224
Age (years) (IQ range)	71.5 (60.5; 79)
Male gender	141 (62.9%)
Diabetes mellitus	53 (23.7%)
Smoking	36 (16.1%)
Previous infarct	69 (30.8%)
Previous use of aspirin	87 (38.8%)
Normal ECG (admission)	157 (70.1%)
ST-segment depression (admission)	28 (12.5%)
Left ventricular failure (admission)	26 (11.7%)
Low-risk TIMI score (TIMI 0-2)	76 (37.6%)
Intermediate-risk TIMI score (TIMI 3-4)	102 (50.5%)
High-risk TIMI score (TIMI 5-7)	24 (11.9%)
GFRe (mL/min) (IQ range)	69.3 (46.7; 92.3)
BNP (pg/mL) (admission) (IQ range)	81.9 (22.2; 225)
Final diagnosis
Unstable angina	117 (52.2%)
NSTEMI	107 (47.8%)

• IQ: interquartile; GFRe: estimated glomerular filtration rate; BNP: B-type natriuretic peptide; NSTEMI: non-ST elevation myocardial infarction; ECG: electrocardiogram

Table 2 demonstrates the relationship between BNP quartiles and clinical and laboratory findings in the 224 NSTEACS patients. It is noteworthy that there was a significant univariate direct relationship with admission BNP levels for most of these variables.

Table 2
Relationship of clinical and laboratory data, final diagnosis and all-cause mortality rate with quartiles of BNP levels (in pg/mL)

	1st quartile	2nd quartile	3rd quartile	4th quartile
	(BNP < 22.2) n = 56	(BNP 22.2-81.9) n = 56	(BNP 82.0-225) n = 56	(BNP > 225)n = 56	p-value
Age (years) (IQ range)	60.5 (51.5; 71.5)	68.5 (58.5; 75)	73.0 (68; 81)	80.0 (73; 84)	p < 0.0001
Previous MI (%)	10 (17.9)	15 (26.8)	21 (37.5)	23 (41.1)	p = 0.0037
Previous use of aspirin (%)	16 (28.6)	23 (41.1)	29 (51.8)	19 (33.9)	p = 0.3594
Admission LV failure (%)	4 (7.3)	2 (3.6)	4 (7.1)	16 (28.6)	p = 0.0004
Admission ST-segment depression (%)	7.1 (4)	10.7 (6)	16.1 (9)	16.1 (9)	p = 0.1050
Admission TIMI Risk Score
Low Risk (TIMI 0-2) (%)	31 (58.5)	19 (38.8)	11 (22.9)	15 (28.8)
Intermediate Risk (TIMI 3-4) (%)	20 (37.7)	25 (51.0)	28 (58.3)	29 (55.8)	p = 0.0002
High Risk (TIMI 5-7) (%)	2 (3.8)	5 (10.2)	9 (18.8)	8 (15.4)
LV dysfunction on Echo (%)	9 (16.4)	16 (30.2)	21 (38.2)	36 (64.3)	p < 0.0001
Final diagnosis
Unstable angina (%)	60.7	64.3	55.4	28.6	p = 0.0004
NSTEMI (%)	39.3	35.7	44.6	71.4	p = 0.0004
All-cause death (%)	8 (14.3)	9 (16.1)	27 (48.2)	41 (73.2)	p < 0.0001

• BNP- B: type natriuretic peptide; IQ: interquartile; MI: myocardial infarction; LV: left ventricle; Echo: echocardiogram; NSTEMI: non-ST elevation myocardial infarction.

During follow-up, 85 patients (37.9%) died in 10 years. Mortality rate increased progressively according to BNP quartiles levels, as depicted in Table 2. Patients who died were older at the index ACS event (79 vs 66 years, p < 0.001), had a worse mean estimated glomerular filtration rate (49.1 vs 80.5 mL/min, p < 0.001), presented more frequently with heart failure on admission (21.2 vs 5.8%, p = 0.001), had more frequently myocardial infarction on admission (61.2 vs 39.6%, p = 0.002) and had higher levels of admission BNP (220 vs 44.7 pg/mL, p < 0.001) than patients who survived.

Prognostic accuracy of BNP levels measured on admission

ROC curve analysis disclosed 100 pg/mL as the best prognostic cut-off value of BNP for 10-year all-cause mortality (area under the curve = 0.789, 95% CI = 0.723 - 0.854). Patients with BNP ≥ 100 pg/mL had a mortality rate of 65% vs 17.3% of those with BNP < 100 pg/mL (relative risk = 3.76, p < 0.001). Sensitivity, specificity, and positive and negative predictive values for mortality were 74.1%, 75.5%, 64.9% and 82.7%, respectively.

The median 10-year survival, as determined by use of the Kaplan-Meier method, was 5.80 years (IQ range = 2.55-9.44) for patients with admission BNP ≥ 100 pg/mL vs 9.63 years (IQ range = 9.04-10.13) for those with BNP < 100 pg/mL (p < 0.0001).

On a multivariate stepwise logistic regression analysis adjusted for all demographic and clinical variables known to be predictors of cardiac death or related to an elevated BNP level (including all variables from Tables 1 and 2), a BNP level of 100 pg/mL obtained upon Emergency Department admission was an independent predictor of 10-year death (Table 3).

Table 3
Independent predictors of 10-year all-cause death by multivariate stepwise logistic regression analysis in patients with non-ST segment elevation acute coronary syndrome

Independent predictors of mortality
Variables	OR (95% CI)	p-value
Age > 72 years	3.79 (1.62-8.86)	p = 0.002
BNP ≥ 100pg/mL	6.24 (2.95-13.23)	p < 0.001
GFRe (for each mL/min increment)	0.98 (0.97-0.99)	p = 0.049

• BNP- B: type natriuretic peptide; GFRe: estimated glomerular filtration rate; OR: odds ratio; CI: confidence interval.

Finally, when using the IDI technique, the addition of BNP information to the traditional risk variables improved prediction and produced an absolute discriminatory increase rate of 3.06% for 10-year mortality (Table 4). The relative discrimination improvement was 10% greater for 10-year mortality with the knowledge and use of BNP information as compared to no use.

Table 4
Comparison of average risk and discrimination improvement using the traditional risk model and the B-type natriuretic peptide (BNP)-added model for 10-year mortality between patients who died (cases) and who survived (controls)

10-year mortality		Average risk	Discrimination improvement
Traditional risk model (without BNP)	Cases	24.931	34.557
	Controls	59.488
BNP-added risk model	Cases	23.766	37.615
	Controls	61.381

• Integrated discrimination improvement: 37.615 – 34.557 = 3.058 (p = 0.0224)
  Relative discrimination improvement: 37.615 / 34.557 = 1.088

TIMI risk score and BNP levels

Information of BNP level further improved risk stratification of the 10-year mortality rate in all three levels of the TIMI risk score, as depicted in Figure 1. The Kaplan-Meier 10-year survival curves of the two levels of BNP value and the three levels of TIMI risk score are depicted in Figures 2 and 3, and clearly disclose a much better discriminative prognostic performance of BNP.

Figure 1
10-year all-cause mortality rates of non-ST segment elevation acute coronary syndrome patients according to the TIMI risk score levels (low = 0-2 points, intermediate = 3-4 points, high= 5-7 points) stratified by optimal C-statistics B-type natriuretic peptide (BNP) cut-off value (in pg/mL).

Figure 2
Kaplan-Meier survival curves of 224 patients with non-ST segment elevation acute coronary syndrome according to admission B-type natriuretic peptide (BNP) level.

Figure 3
Kaplan-Meier survival curves of 202 patients with non-ST segment elevation acute coronary syndrome according to TIMI risk score levels (low = 0-2 points, intermediate = 3-4 points, high = 5-7 points).

Discussion

Several cardiac biomarkers have been proposed and used in the last few decades for prognostic stratification of patients with ACS. The most used are the necrosis markers, specially troponins.^4,5,15,16

Since the year 2000, the immediate- and short-term risk evaluation of cardiovascular outcomes in patients with ACS has been done with the TIMI¹ and the GRACE¹⁷ risk scores as they are relatively easy to calculate at the bedside. It is important to remember that the TIMI risk score was originally tested for a 14-day follow-up; however, several authors have extrapolated its use for longer periods.^18-20 Unfortunately these aggregates of risk factors lack good accuracy for 1-year follow-up as evaluated by the C-statistics of 0.58¹⁸ to 0.69¹⁹ for the TIMI and 0.71¹⁸ to 0.79¹⁹ for the GRACE risk scores. This knowledge has instigated the search for novel and more accurate markers of mortality prediction.^10,21-25

BNP was initially found to be a very early and accurate biochemical marker of acute cardiac contractile dysfunction^26-28 and has been also extensively studied in patients with myocardial ischemia and infarction.^29-31 Its blood concentration increases immediately and rapidly after the beginning of cardiac hypoxia and correlates directly with the extension of myocardial ischemia.^11,32,33 Lately, it has been found to be an excellent prognostic marker of cardiac outcomes in patients with ACS.^6,8,9,34-38 However, most of these studies followed their patients for 1 year, and few of them did it for up to 4 years.^36,39-40

The present study is the first to demonstrate that BNP measured on arrival at the Emergency Department is a strong and independent marker of all-cause death in patients with NSTEACS up to 10 years after the index event, even when compared to the TIMI Risk Score. Our population comes from a consecutive series of patients seen at the Emergency Department with acute chest pain to whom a systematic, careful, comprehensive diagnostic protocol for cardiac ischemia was applied, including the serial measurement of myocardial necrosis markers and ECG, as well as a single BNP sample obtained on admission. Patient's management was left at their private physicians discretion, but most of those with ACS were submitted to coronary angiography and revascularization if found necessary.

BNP was found to remain a powerful and independent marker of all-cause death in the long run in our NSTEACS study sample. BNP also had discriminatory power adding significant prognostic information beyond traditional risk variables for 10-year mortality as seen with the C-statistics. This was confirmed by use of the IDI tool that evaluates the absolute difference between predicted and observed outcome rates, thus representing predictive model's efficiency and consequently allowing comparison of two models. For 10-year mortality, IDI significantly improved outcome discrimination when BNP was used in the model as compared to not used (Table 4), allowing one more patient to obtain a correct outcome classification in a group of 33 individuals.

BNP added significant prognostic information to the TIMI Risk Score of these patients identifying lower and higher risk subgroups (Figure 1). Similar findings were previously demonstrated on a 6-month follow-up study by Bazzino et al.⁶ Contrary to BNP, the TIMI Risk Score itself could not accurately stratify patients for long-term mortality in our study (Figure 3).

Why an elevated BNP measured at an index ACS episode remains as a risk factor of all-cause mortality up to 10 years later is a matter of discussion. As BNP blood levels are not particularly predictive of recurrent fatal and nonfatal myocardial infarction,^6,41 it seems unlikely that late mortality can be explained by a new episode of ACS. It may be speculated that its elevation represents a summation of two well-known prognostic markers in coronary artery disease, that is, the presence and extension of left ventricular ischemia and dysfunction.^7,42,43 The findings of our study could be useful in treatment strategy decision as some authors have suggested that BNP-therapy-guided interventions might improve mortality after ACS.^44,45

Limitations of the study

The present study sample is relatively small in comparison with other cited multicenter studies and originates from a single, private, cardiology-oriented institution. This study does not address the possible value of serial BNP measurements. The troponin assay used in this patient sample is of an older generation (non-high sensitive), although many institutions around the world still use it. It must be remembered that the biochemical diagnostic criteria of myocardial infarction have changed at least twice in the last decade.^46,47

Conclusions

BNP measured on hospital admission in patients with NSTEACS remains a strong, independent predictor of very long-term all-cause mortality, corroborating its excellent risk-stratification capability seen in short- and intermediate-term follow-up studies. This study allows raising the hypothesis that BNP should be measured in all patients with NSTEACS at the index event for long-term risk stratification.

Acknowledgement

This study was partially funded by Hospital Pró-Cardíaco, Rio de Janeiro, Brazil, from where all the data were collected. This manuscript is part of the Master's thesis in Science of Fernando Bassan at the Cardiology Chair, Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro, Brazil.

References

• ¹
  Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000;284(7):835-42.
• ²
  Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation. 2000;101(22):2557-67.
• ³
  Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, et al; GRACE Investigators. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004;291(22):2727-33.
• ⁴
  Newby LK, Christenson RH, Ohman EM, Armstrong PW, Thompson TD, Lee KL, et al. Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators. Circulation. 1998;98(18):1853-9.
• ⁵
  Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996;335(18):1342-9.
• ⁶
  Bazzino O, Fuselli JJ, Botto F, Perez De Arenaza D, Bahit C, Dadone J; PACS group of investigators. Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostic classification and other risk markers in patients with non-ST-elevation acute coronary syndromes. Eur Heart J. 2004;25(10):859-66.
• ⁷
  Estrada JL, Rubinstein FF, Bahit MC, Rolandi FF, de Arenaza DD, Gabay JM, et al; PACS Investigators. NT-probrain natriuretic peptide predicts complexity and severity of the coronary lesions in patients with non-ST-elevation acute coronary syndromes. Am Heart J 2006;151(5):1093.
• ⁸
  Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002;105(15):1760-3.
• ⁹
  Kwan G, Isakson SR, Beede J, Clopton P, Maisel AS, Fitzgerald RL. Short-term serial sampling of natriuretic peptides in patients presenting with chest pain. J Am Coll Cardiol. 2007;49(11):1186-92.
• ¹⁰
  Eggers KM, Kempf T, Venge P, Wallentin L, Wollert KC, Lindahl B. Improving long-term risk prediction in patients with acute chest pain: the Global Registry of Acute Coronary Events (GRACE) risk score is enhanced by selected nonnecrose biomarkers. Am Heart J. 2010;160(1):88-94.
• ¹¹
  Bassan R, Potsch A, Maisel A, Tura B, Villacorta H, Nogueira MV, et al. B-type natriuretic peptide: a novel early blood marker of acute myocardial infarction in patients with chest pain and no ST segment elevation. Eur Heart J. 2005;26(3):234-40.
• ¹²
  Apple FS, Jesse RL, Newby LK, Wu AH, Christenson RH, National Academy of Clinical Biochemistry, IFCC Committee for Standardization of Markers of Cardiac Damage. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical issues for biochemical markers of acute coronary syndromes. Circulation. 2007;115(13):e352-5.
• ¹³
  Jaffe A. Caveat emptor. Am J Med. 2003;115(3):241-4.
• ¹⁴
  Cook NR, Ridker PM. Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med. 2009;150(11):795-802.
• ¹⁵
  Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med. 1996;335(18):1333-41.
• ¹⁶
  Heidenreich PA, Alloggiamento T, Melsop K, McDonald KM, Go AS, Hlatky MA. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. J Am Coll Cardiol. 2001;38(2):478-85.
• ¹⁷
  GRACE Investigators. Rationale and design of the GRACE (Global Registry of Acute Coronariana Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J. 2001;141(2):190-9.
• ¹⁸
  de Araújo Gonçalves P, Ferreira J, Aguiar C, Seabra-Gomes R. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur Heart J. 2005;26(9):865-72.
• ¹⁹
  Yan AT, Yan RT, Tan M, Casanova A, Labinaz M, Sridhar K, et al. Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better. Eur Heart J. 2007;28(9):1072-8.
• ²⁰
  Singh M, Reeder GS, Jacobsen SJ, Weston S, Killian J, Roger VL. Scores for post-myocardial infarction risk stratification in the community. Circulation. 2002;106(18):2309-14.
• ²¹
  Lindahl B. Acute coronary syndrome - the present and future role of biomarkers. Clin Chem Lab Med. 2013;51(9):1699-706.
• ²²
  He LP, Tang XY, Ling WH, Chen WQ, Chen YM. Early C-reactive protein in the prediction of long-term outcomes after acute coronary syndromes: a meta-analysis of longitudinal studies. Heart. 2010;96(5):339-46.
• ²³
  Ferraro S, Marano G, Biganzoli EM, Boracchi P, Bongo AS. Prognostic value of cystatin C in acute coronary syndromes: enhancer of atherosclerosis and promising therapeutic target. Clin Chem Lab Med. 2011;49(9):1397-404.
• ²⁴
  Widera C, Pencina MJ, Bobadilla M, Reimann I, Guba-Quint A, Marquardt I, et al. Incremental prognostic value of biomarkers beyond the GRACE (Global Registry of Acute Coronary Events) score and high-sensitivity cardiac troponin T in non-ST-elevation acute coronary syndrome. Clin Chem. 2013;59(10):1497-505.
• ²⁵
  O'Malley RG, Bonaca MP, Scirica BM, Murphy SA, Jarolim P, Sabatine MS, et al. Prognostic perfomance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36. J Am Coll Cardiol. 2014;63(16):1644-53. Erratum in: J Am Coll Cardiol. 2014;63(23):2642.
• ²⁶
  Felker GM, Petersen JW, Mark DB. Natriuretic peptides in the diagnosis and management of heart failure. CMAJ. 2006;175(6):611-7.
• ²⁷
  Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al; Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161-7.
• ²⁸
  McCullough PA, Nowak RM, McCord J, Hollander JE, Herrmann HC, Steg PG, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation. 2002;106(4):416-22.
• ²⁹
  Arakawa N, Nakamura M, Aoki H, Hiramori K. Relationship between plasma level of brain natriuretic peptide and myocardial infarct size. Cardiology. 1994;85(5):334-40.
• ³⁰
  Nagaya N, Nishikimi T, Goto Y, Miyao Y, Kobayashi Y, Morii I, et al. Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. Am Heart J. 1998;135(1):21-8.
• ³¹
  de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345(14):1014-21.
• ³²
  Marumoto K, Hamada M, Hiwada K. Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischaemia induced by dynamic exercise in patients with angina pectoris. Clin Sci (Lond). 1995;88(5):551-6.
• ³³
  Tateishi J, Masutani M, Ohyanagi M, Iwasaki T. Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clin Cardiol. 2000;23(10):776-80.
• ³⁴
  James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation. 2003;108(3):275-81.
• ³⁵
  Bassan R, Tura BR, Maisel AS. B-type natriuretic peptide: a strong predictor of early and late mortality in patients with acute chest pain without ST-segment elevation in the emergency department. Coron Artery Dis. 2009;20(2):143-9.
• ³⁶
  Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation. 2002;106(23):2913-8.
• ³⁷
  Khan SQ, Quinn P, Davies JE, Ng LL. N-terminal pro-B-type natriuretic peptide is better than TIMI risk score at predicting death after acute myocardial infarction. Heart. 2008;94(1):40-3.
• ³⁸
  García-Alvarez A, Regueiro A, Hernández J, Kasa G, Sitges M, Bosch X, et al. Additional value of B-type natriuretic peptide on discrimination of patients at risk for mortality after a non-ST segment elevation acute coronary syndrome. Eur Heart J Acute Cardiovasc Care. 2014;3(2):132-40.
• ³⁹
  Scotti AV, Tura BR, Rocha RG, Albuquerque DC. Prognostic value of b-type natriuretic peptide in the mortality of patients with acute coronary syndrome. Arq Bras Cardiol. 2012;99(1):605-12.
• ⁴⁰
  Zeng X, Li L, Su Q. The prognostic value of n-terminal pro-brain natriuretic peptide in non-ST elevation acute coronary syndromes: a meta-analysis. Clin Chem Lab Med. 2012;50(4):731-9.
• ⁴¹
  Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, DiBattiste PM, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable Angina/Non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol. 2003;41(8):1264-72. Erratum in: J Am Coll Cardiol. 2003;41(10):1852.
• ⁴²
  Kaul S, Senior R, Firschke C, Wang XQ, Lindner J, Villanueva FS, et al. Incremental value of cardiac imaging in patients presenting to the emergency department with chest pain and without ST-segment elevation: a multicenter study. Am Heart J 2004;148(1):129-36.
• ⁴³
  Rinkevich D, Kaul S, Wang XQ, Tong KL, Belcik T, Kalvaitis S, et al. Regional left ventricular perfusion and function in patients presenting to the emergency department with chest pain and no ST-segment elevation. Eur Heart J 2005;26(16):1606-11.
• ⁴⁴
  Jernberg T, Lindahl B, Siegbahn A, Andren B, Frostfeldt G, Lagerqvist B, et al. N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol. 2003;42:1909-16.
• ⁴⁵
  James SK, Lindbäck J, Tilly J, Siegbahn A, Venge P, Armstrong P, et al. Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy. J Am Coll Cardiol. 2006;48(6):1146-54.
• ⁴⁶
  Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J. 2007;28(20):2525-38.
• ⁴⁷
  Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman R, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Universal definition of myocardial infarction. Third Universal Definition of Myocardial Infarction. J Am Coll Cardiol. 2012;60(16):1581-98.

• Sources of Funding
  There were no external funding sources for this study.

Publication Dates

• Publication in this collection
  02 Feb 2016
• Date of issue
  Mar 2016

History

• Received
  08 June 2015
• Reviewed
  13 Oct 2015
• Accepted
  14 Oct 2015